FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023112189> ?p ?o ?g. }

• W2023112189 endingPage "S281" @default.
• W2023112189 startingPage "S280" @default.
• W2023112189 abstract "Non-myeloablative (NST) and reduced intensity (RIC) regimens are offered to older patients (pts) and/or those with comorbidities because the morbidity and mortality attributable to fully myeloablative conditioning is thought to be unacceptably high. All such patients receive myeloablative protocols in our program, outcomes have been analyzed in order to determine whether this practice is justifiable. Between 1999 and 2008 207 patients (pts) with hematologic malignancy aged 50–66 years (median 56) received blood cell (87%) or marrow transplants after conditioning with Flu 50 mg/m2 daily × 5 and IV Bu 3.2 mg/kg daily × 4. 90 (43%) had additional total body irradiation (TBI) 200 cGy × 2. Graft-versus-host disease (GVHD) prophylaxis was cyclosporin A, methotrexate and Thymoglobulin (Genzyme) 4.5 mg/kg total dose. Donors were matched siblings in 125 (60%) mismatched related in 11 (5%), 10/10 matched unrelated in 54 (26%) and mismatched unrelated in 17(8%). 74 pts (36%) had low-risk (LR, acute leukemia CR1/CR2, CML CP1) disease. As defined by the HCT-CI scoring system 117 (57%) pts scored 0 (low HCT-CI), 68 (33%) 1 or 2 (intermediate HCT-CI) and 22 (11%,) ≥3 (high HCT-CI). Transplant risk factors were similar between intermediate and high HCT-CI groups. As NRM (33% and 33% vs 24% and 48%, p=ns) and DFS (46% and 37% vs 64% and 43%, p=ns) at 1 and 5 years respectively were also similar, outcomes in these 2 groups were combined for more robust analysis. The proportion of pts with LR disease was higher in those with comorbidities (intermediate and high HCT-CI) (49% vs 26%, p=0.0006) than those without. OS was 56% and 39% vs 74% and 54% (p=0.008), DFS 50% and 38% vs 68% and 49% (p=0.03), NRM 31% and 39% vs 15% and 19% (p=0.003) and relapse 26% and 36% vs19% and 39% (p=ns) respectively at 1 and 5 years. In 48 AML pts in CR1 & CR2, 27 (56%) with comorbidities, receiving this protocol with TBI DFS at 5 years was 66%. We conclude that: 1. Comorbidities influence NRM with this regimen although cannot confirm that the high HCT-CI group is at higher risk than the intermediate. 2. Age alone should not be an indication to prefer a less intense protocol particularly in a condition such as AML where there is an effect of regimen intensity on relapse. 3. Although NRM with this regimen is high in older patients with comorbidities, formal comparison with similar patients receiving NST or RIC regimens is warranted." @default.
• W2023112189 created "2016-06-24" @default.
• W2023112189 creator A5016527172 @default.
• W2023112189 creator A5021690248 @default.
• W2023112189 creator A5025720984 @default.
• W2023112189 creator A5027466396 @default.
• W2023112189 creator A5028285126 @default.
• W2023112189 creator A5035692807 @default.
• W2023112189 creator A5036560661 @default.
• W2023112189 creator A5048144508 @default.
• W2023112189 creator A5049766214 @default.
• W2023112189 creator A5050181720 @default.
• W2023112189 creator A5065238694 @default.
• W2023112189 creator A5068947490 @default.
• W2023112189 creator A5074432620 @default.
• W2023112189 creator A5084879148 @default.
• W2023112189 creator A5091623372 @default.
• W2023112189 date "2010-02-01" @default.
• W2023112189 modified "2023-09-27" @default.
• W2023112189 title "Influence Of Comorbidities On Transplant Outcomes In Patients Aged 50 Years Or More After Myeloablative Conditioning Incorporating Fludarabine, Busulfan And ATG" @default.
• W2023112189 doi "https://doi.org/10.1016/j.bbmt.2009.12.374" @default.
• W2023112189 hasPublicationYear "2010" @default.
• W2023112189 type Work @default.
• W2023112189 sameAs 2023112189 @default.
• W2023112189 citedByCount "0" @default.
• W2023112189 crossrefType "journal-article" @default.
• W2023112189 hasAuthorship W2023112189A5016527172 @default.
• W2023112189 hasAuthorship W2023112189A5021690248 @default.
• W2023112189 hasAuthorship W2023112189A5025720984 @default.
• W2023112189 hasAuthorship W2023112189A5027466396 @default.
• W2023112189 hasAuthorship W2023112189A5028285126 @default.
• W2023112189 hasAuthorship W2023112189A5035692807 @default.
• W2023112189 hasAuthorship W2023112189A5036560661 @default.
• W2023112189 hasAuthorship W2023112189A5048144508 @default.
• W2023112189 hasAuthorship W2023112189A5049766214 @default.
• W2023112189 hasAuthorship W2023112189A5050181720 @default.
• W2023112189 hasAuthorship W2023112189A5065238694 @default.
• W2023112189 hasAuthorship W2023112189A5068947490 @default.
• W2023112189 hasAuthorship W2023112189A5074432620 @default.
• W2023112189 hasAuthorship W2023112189A5084879148 @default.
• W2023112189 hasAuthorship W2023112189A5091623372 @default.
• W2023112189 hasBestOaLocation W20231121891 @default.
• W2023112189 hasConcept C126322002 @default.
• W2023112189 hasConcept C141071460 @default.
• W2023112189 hasConcept C2776694085 @default.
• W2023112189 hasConcept C2776755627 @default.
• W2023112189 hasConcept C2777408962 @default.
• W2023112189 hasConcept C2777630719 @default.
• W2023112189 hasConcept C2778684742 @default.
• W2023112189 hasConcept C2778880498 @default.
• W2023112189 hasConcept C2779263901 @default.
• W2023112189 hasConcept C2780611847 @default.
• W2023112189 hasConcept C2781059491 @default.
• W2023112189 hasConcept C2909675724 @default.
• W2023112189 hasConcept C2911091166 @default.
• W2023112189 hasConcept C71924100 @default.
• W2023112189 hasConcept C90924648 @default.
• W2023112189 hasConceptScore W2023112189C126322002 @default.
• W2023112189 hasConceptScore W2023112189C141071460 @default.
• W2023112189 hasConceptScore W2023112189C2776694085 @default.
• W2023112189 hasConceptScore W2023112189C2776755627 @default.
• W2023112189 hasConceptScore W2023112189C2777408962 @default.
• W2023112189 hasConceptScore W2023112189C2777630719 @default.
• W2023112189 hasConceptScore W2023112189C2778684742 @default.
• W2023112189 hasConceptScore W2023112189C2778880498 @default.
• W2023112189 hasConceptScore W2023112189C2779263901 @default.
• W2023112189 hasConceptScore W2023112189C2780611847 @default.
• W2023112189 hasConceptScore W2023112189C2781059491 @default.
• W2023112189 hasConceptScore W2023112189C2909675724 @default.
• W2023112189 hasConceptScore W2023112189C2911091166 @default.
• W2023112189 hasConceptScore W2023112189C71924100 @default.
• W2023112189 hasConceptScore W2023112189C90924648 @default.
• W2023112189 hasIssue "2" @default.
• W2023112189 hasLocation W20231121891 @default.
• W2023112189 hasOpenAccess W2023112189 @default.
• W2023112189 hasPrimaryLocation W20231121891 @default.
• W2023112189 hasRelatedWork W100404521 @default.
• W2023112189 hasRelatedWork W2004319386 @default.
• W2023112189 hasRelatedWork W2080636075 @default.
• W2023112189 hasRelatedWork W2530463753 @default.
• W2023112189 hasRelatedWork W2562368003 @default.
• W2023112189 hasRelatedWork W2979354104 @default.
• W2023112189 hasRelatedWork W2979908979 @default.
• W2023112189 hasRelatedWork W3096751439 @default.
• W2023112189 hasRelatedWork W4310956126 @default.
• W2023112189 hasRelatedWork W4381470110 @default.
• W2023112189 hasVolume "16" @default.
• W2023112189 isParatext "false" @default.
• W2023112189 isRetracted "false" @default.
• W2023112189 magId "2023112189" @default.
• W2023112189 workType "article" @default.